top of page
iPharmaCenter
ipharmacenter Consulting services
ipharmacenter
Consulting services
ipharmacenter
Consulting services
ipharmacenter
Consulting services
Home
Pharma
US FDA Approvals
North America
China Drug Approvals
Japan Drug Approvals | Healthcare
India Drug Approvals
APAC - Drug Approvals
LACAM
Europe
Canada Drug Healthcare News
Brazil - Drug approvals
EMA News
APAC
Therapy News
Immunology
Neurology
Oncology
Kidney Diseases
Cardiovascular
Infections_Vaccines
Metabolic Diseases
Women Health
Healthcare News
US Healthcare News
US Payer News
Europe Healthcare News
NICE Assessment Outcomes
G-BA Assessment Outcomes
APAC - Healthcare News
Lacam Healthcare News
Healthcare Policies
Conferences
All News
For sponsored articles, link insertions, and advertisements, please write to
info@ipharmacenter.com
All Posts
Healthcare Systems
News
Conferences
Know your disease
COVID
Japan drug approvals
USA Pharma News | Healthcare News
Europe Pharma News
Japan drug approvals
Australia Pharma & Healthcare News
Canada Pharma and Healthcare News
Asia | Pharma | Healthcare News
Indication News
Latam
US FDA News
CMS News
India Drug Healthcare
China Drug Approvals
Europe Healthcare News
APAC Drug approvals
US_PayerNews
Australia TGA Approvals
Biosimilars
Radioligand therapy
Chikungunya News
NICE recommendations
G-BA Assessment Outcomes
HAS Assessment Outcomes
Neurology
Immunology
Search
Bristol Myers Squibb Reports Positive Results from Phase 3 Trials of Deucravacitinib in Psoriatic Arthritis | iPharmaCenter
Bristol Myers Squibb has announced encouraging findings from two key Phase 3 trials, POETYK PsA-1 and POETYK PsA-2, evaluating...
ipharmaservices
Dec 27, 2024
Lilly Secures FDA Approval for Zepbound in Obstructive Sleep Apnea, Outpacing Novo Nordisk | Pharma Breaking News | iPharmaCenter
Eli Lilly has achieved a significant milestone by securing U.S. Food and Drug Administration (FDA) approval for Zepbound (tirzepatide) as...
ipharmaservices
Dec 23, 2024
bottom of page
